<DOC>
	<DOCNO>NCT00833872</DOCNO>
	<brief_summary>The purpose first-in-man trial determine safety tolerability ascend single multiple dos LEO 22811 healthy male subject well determine safety tolerability single oral dos LEO 22811 healthy female subject . The trial perform two part . In Part 1 , single dos LEO 22811 administer healthy male female subject . In Part 2 , multiple dos LEO 22811 administer healthy male subject .</brief_summary>
	<brief_title>LEO 22811 - A Phase 1 , Double-Blind , Placebo-controlled , Single Multiple Oral Dose Study Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>( summary ) Subjects Caucasian male female nonchild bear potential 18 65 year age Subjects give write informed consent participate study abide study restriction ( summary ) Women childbearing potential Subjects infectious illness within 3 day prior dose Subjects history tuberculosis Subjects receive prescribed systemic topical medication ( include natural/herbal medicine ) within 14 day first dose administration Subjects use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day first dose administration In Part 2 , subject receive exposed Cloroquine product , endoxan , immunomodulating agent ( e.g . azathioprin ) within one month prior start dose Subjects participate clinical study Subjects significant history drug allergy know suspected hypersensitivity component LEO 22811 determine Investigator Subjects clinically significant allergic disease ( exclude nonactive hayfever ) determine Investigator Subjects supine blood pressure supine pulse rate screen high 150/90 mmHg 100 beat per minute ( bpm ) , respectively , low 90/40 mmHg 50 bpm , respectively Subjects PR interval &gt; = 200 m , QTc ( b ) interval &gt; 450 m ( male ) &gt; 470 m ( female ) , exhibit U wave atrioventricular block screen , base 12lead ECGs Subjects consume 28 unit ( male ) 21 unit ( female ) alcohol per week significant history alcoholism drug/chemical abuse Subjects smoke 5 cigarette equivalent tobacco per day Subjects significant cardiac history ( e.g . heart failure , hypokalemia , long QT syndrome ) Subjects clinically significant illness within 4 week start dose administration determine Investigator Subjects , opinion General Practitioner ( GP ) Investigator , participate study , include subject suspect whatever reason able comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>